Antagonist antibodies to human prolactin receptor (PRLR)
The present invention provides antibodies that bind to prolactin receptor (PRLR) and methods of using the same. According to certain embodiments, the antibodies of the invention bind human PRLR with high affinity. In certain embodiments, the invention includes antibodies that bind PRLR and block prolactin-mediated cell signaling. In other embodiments, the invention includes antibodies that bind PRLR but do not block prolactin-mediated cell signaling. The antibodies of the invention may be fully human antibodies. The invention includes anti-PRLR antibodies conjugated to a cytotoxic agent, radionuclide, or other moiety detrimental to cell growth or proliferation. The antibodies of the invention are useful for the treatment of various cancers as well as other PRLR-related disorders. The present invention also includes antibody drug conjugates comprising an antibody or antigen-binding fragment thereof that specifically binds a class I cytokine receptor, wherein the antibody or antigen-binding fragment thereof is conjugated to a cytotoxic agent.
1. An isolated antibody or antigen-binding fragment thereof that binds to cell surface-expressed human prolactin receptor (PRLR) and blocks prolactin-mediated signaling in cells expressing human PRLR, comprising (i) a heavy chain variable domain comprising an amino acid sequence having at least 95% identity to SEQ ID NO: 290 and (ii) a light chain variable domain comprising an amino acid sequence having at least 95% identity to SEQ ID NO: 298.
2. The antibody or antigen-binding fragment thereof of claim 1 , wherein the heavy chain variable domain comprises an amino acid sequence having at least 98% identity to SEQ ID NO: 290.
3. The antibody or antigen-binding fragment thereof of claim 1 , wherein the heavy chain variable domain comprises an amino acid sequence having at least 99% identity to SEQ ID NO: 290.
4. The antibody or antigen-binding fragment thereof of claim 1 , wherein the light chain variable domain comprises an amino acid sequence having at least 98% identity to SEQ ID NO: 298.
5. The antibody or antigen-binding fragment thereof of claim 1 , wherein the light chain variable domain comprises an amino acid sequence having at least 99% identity to SEQ ID NO: 298.
6. An antibody-drug conjugate (ADC) comprising the antibody or antigen-binding fragment thereof of claim 1 conjugated to a cytotoxic agent, wherein the ADC inhibits the growth of cells expressing PRLR.
7. The ADC of claim 6 , wherein the cytotoxic agent is an auristatin, a calicheamicin, a doxorubicin, a duocarmycin, a maytansinoid, or a tubulysin.
8. The ADC of claim 7 , wherein the cytotoxic agent is a maytansinoid.
9. The ADC of claim 8 , wherein the maytansinoid is DM1 or DM4.
10. The ADC of claim 8 , wherein the maytansinoid is conjugated to the antibody via a cleavable linker.
11. The ADC of claim 8 , wherein the maytansinoid is conjugated to the antibody via a non-cleavable linker.
12. The ADC of claim 8 , wherein the maytansinoid is conjugated to the antibody via a linker comprising MC (6-maleimidocaproyl), MP (maleimidopropanoyl), val-cit (valine-citrulline), val-ala (valine-alanine), dipeptide site in protease-cleavable linker, ala-phe (alanine-phenylalanine), dipeptide site in protease-cleavable linker, PAB (p-aminobenzyloxycarbonyl), SPP (N-Succinimidyl 4-(2-pyridylthio) pentanoate), SMCC (N-Succinimidyl 4-(N-maleimidomethyl)cyclohexane-1 carboxylate), or SIAB (N-Succinimidyl (4-iodo-acetyl)aminobenzoate).
13. The ADC of claim 9 , wherein the maytansinoid is conjugated to the antibody or antigen-binding fragment thereof via an N-succinimidyl 4-(N-maleimidomethyl) cyclohexane-1-carboxylate (SMCC) linker.
14. The ADC of claim 7 , wherein the cytotoxic agent is DM1.
15. The ADC of claim 7 , wherein the ADC is a compound of formula I:
wherein Ab is the antibody or antigen-binding fragment thereof.
16. A pharmaceutical composition comprising the ADC of claim 6 and a pharmaceutically acceptable carrier or diluent.